Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Share-based Compensation (2023 - 2025)

Camp4 Therapeutics' Share-based Compensation history spans 3 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 44.42% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.0 million, down 0.84%, while the annual FY2025 figure was $4.0 million, 0.84% down from the prior year.
  • Share-based Compensation for Q4 2025 was $1.2 million at Camp4 Therapeutics, up from $984000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.6 million in Q3 2024 and bottomed at $636000.0 in Q4 2023.
  • The 3-year median for Share-based Compensation is $861000.0 (2025), against an average of $962888.9.
  • The largest YoY upside for Share-based Compensation was 44.42% in 2025 against a maximum downside of 38.23% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $636000.0 in 2023, then increased by 25.31% to $797000.0 in 2024, then skyrocketed by 44.42% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Share-based Compensation are $1.2 million (Q4 2025), $984000.0 (Q3 2025), and $1.0 million (Q2 2025).